Sponsors (13)
Introduced November 19, 2025 by Elizabeth Warren · Last progress November 19, 2025
The bill increases transparency, public participation, equity analysis, and speed/clarity in rulemaking—benefiting many citizens and businesses—while concentrating power in agencies, adding administrative burdens and disclosure requirements that risk rushed or less contestable regulations and potential privacy, litigation, and compliance costs.
Millions of Americans, including taxpayers, nonprofits, small businesses, and state/local governments, gain substantially increased transparency and easier avenues to participate in rulemaking because agencies must publish notices quickly, keep participation logs, create online dockets, respond to large‑signature petitions, disclose draft-to-final changes, and explain withdrawals.
Businesses, regulated parties, and the public get faster, more predictable regulatory timelines because the bill imposes clear deadlines for rulemaking steps, limits extended review delays (including OIRA deadline rules), and creates mechanisms to restore previously disapproved rules quickly.
Low‑income communities, racial/ethnic minorities, and other disadvantaged groups may benefit from rules that more explicitly consider distributional, social equity, and nonquantifiable public‑health and safety benefits because agencies must assess and publish equity and distributional impacts and can prioritize public benefits.
Millions of Americans and regulated parties may face broader executive‑branch regulatory power and reduced judicial checks because the bill expands deference to agencies and limits judicial review in several ways, making it harder to challenge agency interpretations and actions.
Agencies, taxpayers, and regulated entities will incur substantial new administrative costs and resource burdens—hiring staff, maintaining logs/dockets, conducting rapid equity assessments, collecting disclosures, and meeting tight publication deadlines—which could increase government spending and compliance costs passed to the public.
Disclosure rules for outside studies and publication of participation logs risk exposing sensitive commercial, proprietary, or personal information and may chill researchers and businesses from submitting evidence or participating fully in rulemakings.
Based on analysis of 19 sections of legislative text.
Overhauls federal rulemaking: creates a Public Advocate, increases transparency and disclosure (including researcher funding), raises penalties for false submissions by public companies, expands agency deference, and sets review deadlines.
The bill rewrites how federal rulemaking works by creating an Office of the Public Advocate at OMB, expanding agency transparency and timelines, and changing how courts review agency actions. It requires agencies to disclose drafts, differences from OMB review, and conflicts of interest for submitted scientific or technical studies; it forces agencies to respond to large petitions and to complete OIRA review within set time limits. The bill also imposes large civil penalties on public companies that knowingly submit materially false or misleading materials to agencies, allows agencies to republish certain previously disapproved rules for a limited time, requires social equity assessments and consideration of nonquantifiable public benefits in regulatory analyses, and sets a six-year statute of limitations for judicial review of agency actions.